Search: onr:"swepub:oai:DiVA.org:uu-346995" >
Prospective observa...
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs) : feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity
-
- Garske, Ulrike, 1963- (author)
- Uppsala universitet,Radiologi,Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden
-
- Sandström, Mattias (author)
- Uppsala universitet,Radiologi
-
- Fröss-Baron, Katarzyna (author)
- Uppsala universitet,Endokrin tumörbiologi
-
show more...
-
- Lundin, Lars (author)
- Uppsala universitet,Radiologi
-
- Hellman, Per (author)
- Uppsala universitet,Endokrinkirurgi
-
- Welin, Staffan (author)
- Uppsala universitet,Onkologisk endokrinologi
-
- Johansson, Silvia (author)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Khan, Tanweera Shaheena (author)
- Uppsala universitet,Endokrin tumörbiologi
-
- Lundqvist, Hans (author)
- Uppsala universitet,Medicinsk strålningsvetenskap
-
- Eriksson, Barbro (author)
- Uppsala universitet,Endokrin tumörbiologi
-
- Sundin, Anders, 1954- (author)
- Uppsala universitet,Radiologi
-
- Granberg, Dan (author)
- Karolinska Institutet,Uppsala universitet,Onkologisk endokrinologi
-
show less...
-
(creator_code:org_t)
- 2018-03-01
- 2018
- English.
-
In: European Journal of Nuclear Medicine and Molecular Imaging. - : Springer Science and Business Media LLC. - 1619-7070 .- 1619-7089. ; 45:6, s. 970-988
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://uu.diva-port... (primary) (Raw object)
-
https://link.springe...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- PURPOSE: Peptide receptor radionuclide therapy in patients with neuroendocrine tumours has yielded promising results. This prospective study investigated the feasibility of dosimetry of the kidneys and bone marrow during therapy and its impact on efficacy and outcome.METHODS: Lu-DOTA-octreotate with co-infusion of a mixed amino acid solution, and cycles were repeated until the absorbed dose to the kidneys reached 23 Gy or there were other reasons for stopping therapy. The Ki-67 index was ≤2% in 47 patients (23.5%), 3-20% in 121 (60.5%) and >20% in 16 (8%).RESULTS: In 123 patients (61.5%) the absorbed dose to the kidneys reached 23 Gy with three to nine cycles during first-line therapy; in no patient was a dose to the bone marrow of 2 Gy reached. The best responses (according to RECIST 1.1) were a complete response (CR) in 1 patient (0.5%), a partial response (PR) in 47 (23.5%), stable disease (SD) in 135 (67.5%) and progressive disease (PD) in 7 (3.5%). Median progression-free survival was 27 months (95% CI 22-30 months) in all patients, 33 months in those in whom the absorbed dose to the kidneys reached 23 Gy and 15 months in those in whom it did not. Median overall survival (OS) was 43 months (95% CI 39-53 months) in all patients, 54 months in those in whom the absorbed dose to the kidneys reached 23 Gy and 25 months in those in whom it did not. Median OS was 60 months in patients with a best response of PR or CR, 42 months in those with SD and 16 months in those with PD. Three patients (1.5%) developed acute leukaemia, 1 patient (0.5%) chronic leukaemia (unconfirmed) and 30 patients (15%) grade 3 or 4 bone marrow toxicity. Eight patients (4%) developed grade 2 kidney toxicity and one patient (0.5%) grade 4 kidney toxicity.CONCLUSIONS: Lu-DOTA-octreotate is feasible. Patients in whom the absorbed dose to the kidneys reached 23 Gy had a longer OS than those in whom it did not. Patients with CR/PR had a longer OS than those with SD. Bone marrow dosimetry did not predict toxicity.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- 177Lu-DOTA-octreotate
- Dosimetry
- Neuroendocrine tumour
- Outcome
- PRRT
- Toxicity
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Garske, Ulrike, ...
-
Sandström, Matti ...
-
Fröss-Baron, Kat ...
-
Lundin, Lars
-
Hellman, Per
-
Welin, Staffan
-
show more...
-
Johansson, Silvi ...
-
Khan, Tanweera S ...
-
Lundqvist, Hans
-
Eriksson, Barbro
-
Sundin, Anders, ...
-
Granberg, Dan
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Radiology Nuclea ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
European Journal ...
- By the university
-
Uppsala University
-
Karolinska Institutet